- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
DEPO Market Currents
more »
-
May 8 More on Depomed (DEPO): Q1 beats across the board on fewer than anticipated losses, despite an 80% Y/Y decline in total revenue, largely attributed to licensing revenue and a milestone payment from Abbott Labs. Shares -0.4% AH.
Comment![Earnings, Healthcare]
DEPO in Focus
more »
DEPO Related Articles
more »
DEPO News
more »
-
at MarketWatch.com (Feb 6, 2012)
-
at MarketWatch.com (Oct 14, 2011)
-
at MarketWatch.com (Oct 14, 2011)
-
at MarketWatch.com (May 6, 2011)
-
at MarketWatch.com (Feb 15, 2011)
DEPO Press Releases and Filings
more »
-
PR Newswire (Fri, 8:00AM)
-
PR Newswire (May 11, 2012)
-
PR Newswire (May 10, 2012)
-
PR Newswire (May 8, 2012)
-
GlobeNewswire (May 1, 2012)
DEPO Latest Transcript
more »
-
Mon, May 3, 2010
DEPO Cramer
more »
-
Wed, May 3, 2006
DEPO Instablog posts
more »
DEPO vs. ETF Alternatives
Company Description
Depomed is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that address large and growing markets and are based on proprietary oral drug delivery technologies. In 2009, we completed Phase 3 clinical trials for two product... More
